Zevra Therapeutics (ZVRA) Invested Capital (2014 - 2026)

Zevra Therapeutics has reported Invested Capital for 13 years, with the latest figure at $205.8 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 401.68% year-over-year to $205.8 million; the trailing twelve-month figure through Mar 2026 stood at $205.8 million (up 401.68% YoY), and the FY2025 full-year result was $216.6 million, up 118.4% from the prior year.
• Invested Capital for Q1 2026 stood at $205.8 million, down from $216.6 million in the prior quarter.
• The five-year high for Invested Capital was $432.4 million in Q1 2022, with the low at $32.5 million in Q2 2024.
• Historically, Invested Capital has averaged $122.9 million across 5 years, with a median of $84.5 million in 2022.
• Annual changes were most pronounced in 2023 — Invested Capital tumbled 86.29% — and 2025, when it surged 447.82%.
• Zevra Therapeutics' Invested Capital stood at $75.1 million in 2022, then soared by 32.54% to $99.6 million in 2023, then decreased by 0.4% to $99.2 million in 2024, then surged by 118.4% to $216.6 million in 2025, then decreased by 4.98% to $205.8 million in 2026.
• The last three Invested Capital figures came in at $205.8 million (Q1 2026), $216.6 million (Q4 2025), and $194.5 million (Q3 2025), per Business Quant data.